Evidence map›Paper›PMID 33434674›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching.

Chenlu Huang, Ling Fei, Weixia Li, Wei Xu, Xudong Xie, Qiang Li, Liang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Article
  9. Intravenous immunoglobulins (IVIG) in severe/critical COVID-19 adult patients.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023
    Review
  10. Review
  11. Immune-based therapeutic approaches in COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Therapeutic Agents Rounding Up the Immunopathology of COVID-19.Therapeutics and clinical risk management · 2021
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chenlu HuangDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Ling FeiDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Weixia LiDepartment of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Wei XuDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xudong XieDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Qiang LiDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Electronic address: liqiang66601@163.com.
Liang ChenDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Electronic address: chenliang@shphc.org.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesAt the present time, there is an absence of any proven effective antiviral therapy for patients with coronavirus disease 2019 (COVID-19). The aim of this study was to assess the efficacy of intravenous immunoglobulin (IVIG) in non-severe patients with COVID-19.

methodsA retrospective study based on propensity score matching (PSM) was designed. Primary outcomes included the severity and mortality rates. Secondary outcomes included the duration of fever, virus clearance time, length of hospital stay, and use of antibiotics.

resultsA total of 639 non-severe patients with COVID-19 were enrolled. Forty-five patients received IVIG therapy and 594 received non-IVIG therapy. After PSM (1:2 ratio), the baseline characteristics were well balanced between the IVIG group (n = 45) and control group (n = 90). No statistically significant difference was found between the IVIG group and control group in the duration of fever (median 3 vs 3 days, p = 0.667), virus clearance time (median 11 vs 10 days, p = 0.288), length of hospital stay (median 14 vs 13 days, p = 0.469), or use of antibiotics (40% vs 38.9%, p = 0.901). Meanwhile, compared to the IVIG group, no more patients in the control group progressed to severe disease (3.3% vs 6.6%, p = 0.376) or died (0 vs 2.2%, p = 0.156).

conclusionsIn non-severe patients with COVID-19, no benefit was observed with IVIG therapy beyond standard therapy.

Indexed as

COVID-19 Drug TreatmentPropensity ScoreSARS-CoV-2AdultAgedCOVID-19FemaleHumansImmunoglobulins, IntravenousLength of StayMaleMiddle AgedRetrospective StudiesSeverity of Illness IndexImmunoglobulins, IntravenousCoronavirus disease 2019Efficacy evaluationIntravenous immunoglobulinMortalitySevere acute respiratory syndrome coronavirus 2

Identifiers

PMID33434674
PMCPMC7833031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.